Kirin to Release “Slow Drink(R)” Advertisements Promoting Responsible Drinking in Pursuit of Zero Harmful Drinking During the Holiday Season
10.12.2019 12:30:00 EET | Business Wire | Press release
Kirin Holdings Company, Limited (TOKYO:2503) (President and CEO: Yoshinori Isozaki) plans to begin running advertisements promoting responsible drinking on Twitter (Japanese version) starting Friday, December 6, ahead of the peak season for New Year gatherings. The aim of the ads is to prevent the binge drinking, speed drinking, and other dangerous modes of consuming alcohol often observed at these events, and to promote and encourage responsible drinking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005439/en/
IMAGE(1) (Graphic: Business Wire)
The Company unveiled the Kirin Group CSV1 Purpose, which provides guidelines for creating shared value with society and promoting sustainable growth, and serves as long-term, non-financial targets incorporated into the Kirin Group Vision 2027, which represents the Group’s long-term management vision.
The ad campaign is part of our efforts to play a leading role as a responsible alcohol producer as called for in the CSV Purpose.
1CSV: Creating Shared Value. The premise is about creating value that can be shared with customers and society.
The number of people transported emergently to hospitals for acute alcohol poisoning is increasing each year;2 roughly half of those people are in their 20s. The advertisements emphasize the life-threatening danger of binge drinking and other harmful modes of consuming alcohol, and promote responsible drinking namely to people in their 20s who have little experience with alcohol. The ads also communicate the importance of responsible drinking to fulfill the Company’s social responsibility as a manufacturer and seller of alcoholic beverages.
2According to investigations by the fire departments of Tokyo, Osaka, and Nagoya
The Company also plans to stream subtitled English versions of the advertisements with the aim of sharing the message with the world to address the global social issue of harmful alcohol consumption.
YouTube release of subtitled English version: Link: https://youtu.be/0ORj-ZxJdGs
Title: SLOW DRINK (I was just going a little too fast) English version
The Company is proposing “Slow Drink(R)” as a new method of drinking in which people take a relaxed approach to consuming alcohol: being smart and keeping the situation pleasant by drinking in moderation while enjoying good food and conversation with others.
We have created an official logo for “Slow Drink(R)”, and intend to promote new values for alcohol as part of the public education campaign for responsible drinking we are undertaking as an alcohol producer.
In the business environment in which the Kirin Group operates, companies are under increasing pressure to tackle social issues, which include health problems caused by harmful drinking.
We are committed to promoting zero harmful drinking and ensuring that people will continue to enjoy a responsible drinking culture for generations to come.
The Kirin Group is committed to its role as a responsible alcohol producer and addressing the three key social issues: “health and well-being,” “community engagement,” and “the environment.” By fulfilling these commitments, the Group can bring joy to society and a brighter future to our customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005439/en/
Contact information
For press inquiries, contact:
Corporate Communications Department, Kirin Holdings Co., Ltd.
Tel +81-3-6837-7028
For consumer inquiries, call:
Customer Service, Kirin Holdings Co., Ltd. at 0120-770-502 (toll-free if called from within Japan)
Email address: izawa@ccpr.jp (Ryo Izawa)
Kirin Website: https://www.kirin.co.jp (Images available for download)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
